Glenmark Life Sciences Limited
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and m… Read more
Glenmark Life Sciences Limited (GLS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.011x
Based on the latest financial reports, Glenmark Life Sciences Limited (GLS) has a cash flow conversion efficiency ratio of 0.011x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹262.58 Million) by net assets (₹23.92 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Glenmark Life Sciences Limited - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Glenmark Life Sciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Glenmark Life Sciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Glenmark Life Sciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asseco South Eastern Europe S.A.
WAR:ASE
|
0.038x |
|
Inox Wind Limited
NSE:INOXWIND
|
-0.058x |
|
Beijing Deep Glint Technology Co. Ltd. A
SHG:688207
|
N/A |
|
SIMPAR S.A
SA:SIMH3
|
0.348x |
|
EVN Finance JSC
VN:EVF
|
-0.339x |
|
Prudent Corporate Advisory Services Limited
NSE:PRUDENT
|
0.154x |
|
São Martinho S.A
SA:SMTO3
|
0.046x |
|
StarHub Ltd
F:RYTB
|
0.067x |
Annual Cash Flow Conversion Efficiency for Glenmark Life Sciences Limited (2018–2024)
The table below shows the annual cash flow conversion efficiency of Glenmark Life Sciences Limited from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-03-31 | ₹23.32 Billion | ₹4.14 Billion | 0.177x | +20.96% |
| 2023-03-31 | ₹21.38 Billion | ₹3.13 Billion | 0.147x | -49.61% |
| 2022-03-31 | ₹20.54 Billion | ₹5.98 Billion | 0.291x | -43.58% |
| 2021-03-31 | ₹7.53 Billion | ₹3.88 Billion | 0.516x | +6.21% |
| 2020-03-31 | ₹4.02 Billion | ₹1.95 Billion | 0.485x | +313.27% |
| 2019-03-31 | ₹881.25 Million | ₹103.52 Million | 0.117x | -65.86% |
| 2018-03-31 | ₹-13.98 Million | ₹-4.81 Million | 0.344x | -- |